Holen Sie sich die Stockscreener-App
0.289
1.26%
-0.0037
Handel nachbörslich:
.29
0.001
+0.35%
Schlusskurs vom Vortag:
$0.2927
Offen:
$0.2973
24-Stunden-Volumen:
436.66K
Relative Volume:
0.57
Marktkapitalisierung:
$26.84M
Einnahmen:
$1.22M
Nettoeinkommen (Verlust:
$-14.15M
KGV:
-1.1115
EPS:
-0.26
Netto-Cashflow:
$-6.55M
1W Leistung:
+2.30%
1M Leistung:
-2.99%
6M Leistung:
-4.46%
1J Leistung:
-15.65%
1-Tages-Spanne:
$0.2885
$0.2973
1-Wochen-Bereich:
$0.275
$0.2973
52-Wochen-Spanne:
$0.2525
$0.4985
IGC Pharma Inc Stock (IGC) Company Profile
Firmenname
IGC Pharma Inc
Sektor
Branche
Telefon
301-983-0998
Adresse
4336 Montgomery Avenue, Bethesda, MD
Vergleichen Sie IGC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IGC
IGC Pharma Inc
|
0.289 | 27.18M | 1.22M | -14.15M | -6.55M | -0.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
IGC Pharma Inc Aktie (IGC) Neueste Nachrichten
Can IGC Pharma Inc. (IGS1) stock sustain institutional flowsStock Price Forecasts & Analyze Your Portfolio Risk in Seconds - bollywoodhelpline.com
IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability - Finviz
IGC Pharma (IGC) Aligns Fiscal Year with Calendar Year - GuruFocus
IGC Pharma Announces Registered Direct Equity Offering Financing - TipRanks
IGC Pharma Signs Subscription Agreement With Certain Investors - TradingView — Track All Markets
How IGC Pharma Inc. (IGS1) stock expands through international markets2026 world cup usa national team round of 32 midfield engines high defensive line tactical prediction preview - Улправда
IGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial - BioSpace
IGC Pharma (IGC) Secures Funding Through Share Sale - GuruFocus
Small biotech secures cash to keep its Alzheimer's trial moving - Stock Titan
IGC Pharma Adjusts Fiscal Year-End to December 31 - TipRanks
IGC Pharma increases authorized shares to 600 million - MSN
Operating cash flow per share of IGC Pharma, Inc. – SWB:IGS1 - TradingView — Track All Markets
IGC Pharma Inc. (IGC) Stock Price | Live Quotes & Charts | AMEX - StocksToTrade
Would You Still Hold IGC Pharma Stock If It Fell Another 30%? - Trefis
IGC Pharma (FRA:IGS1) EV-to-OCF : -4.65 (As of Dec. 21, 2025) - GuruFocus
How IGC Pharma Inc. stock responds to policy changesWeekly Trend Summary & Long-Term Capital Growth Strategies - Улправда
IGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum - Big News Network.com
Will IGC Pharma Inc. stock outperform benchmarksInflation Watch & Verified Swing Trading Watchlists - Улправда
IGC Pharma Secures U.S. Patent for Innovative Stuttering Treatme - GuruFocus
What makes IGC Pharma Inc. stock appealing to growth investors2025 Trading Volume Trends & Accurate Buy Signal Notifications - DonanımHaber
How IGC Pharma Inc. stock benefits from strong dollarWeekly Trade Report & High Return Trade Opportunity Guides - DonanımHaber
Can IGC Pharma Inc. stock deliver strong Q4 earningsWeekly Investment Summary & Technical Buy Zone Confirmation - DonanımHaber
Why IGC Pharma Inc. stock remains stableJuly 2025 Selloffs & Low Risk Growth Stock Ideas - DonanımHaber
Aug Analyst Calls: How IGC Pharma Inc. (IGS1) stock expands through international markets2025 Pullback Review & Long-Term Growth Stock Strategies - Улправда
IGC Pharma Inc - Reuters
IGC Pharma comments on potential reclassification of cannabis - MSN
IGC Pharma Increases Authorized Shares to 600 Million - The Globe and Mail
IGC Pharma Positions as a Singular Beneficiary of Emerging Feder - GuruFocus
IGC Pharma (IGC) Advances in FDA-regulated Cannabinoid Drug Deve - GuruFocus
IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cann - pharmiweb.com
IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines - Weatherford Democrat
IGC Pharma Inc IGC’s stock price falss traction on Thursday - uspostnews.com
It is Poised to be a Bull Market for IGC Pharma Inc (IGC) - setenews.com
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75." - Digital Journal
IGC Pharma : Announces Coverage Report by Ascendiant Capital Markets about the “Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75.” - marketscreener.com
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We - pharmiweb.com
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the - Big News Network.com
IGC Pharma Achieves 65% Enrollment In Phase 2 CALMA Trial For Alzheimer's Agitation - Nasdaq
Ascendiant Capital Markets Issues Positive Forecast for IGC Pharma (NYSEMKT:IGC) Stock Price - Defense World
Ascendiant Capital Maintains IGC Pharma (IGC) Buy Recommendation - Nasdaq
IGC Pharma (IGC): Ascendiant Capital Raises Price Target to $4.7 - GuruFocus
IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 C - GuruFocus
IGC Achieves Significant Enrollment Progress in Phase 2 Alzheimer's Trial - GuruFocus
Finanzdaten der IGC Pharma Inc-Aktie (IGC)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):